Company Search:
Advanced Search
Sponsored Links
Genethera, Inc. Company Snapshot
Genethera, Inc. operates in the Biological products exc. diagnostic sector. In addition to historical fundamental analyses, the complete report available to purchase compares Genethera with three other pharmaceutical manufacturers in North America: CEL-SCI Corporation (2008 sales of $5,065.00 of which 100% was Pharmaceutical Prod), Nutra Pharma Corporation ($4,045.00 of which 100% was Development of Drugs), and Oncotelic Therapeutics Inc ($12,000.00 of which 100% was Physical Research).

Sales Analysis. During the first quarter of 2008, sales at Genethera totalled $10,821.00 . Sales fell dramatically in 2008: Genethera reported sales of $10,822.00 for the year ending December of 2008. This represents a sharp decrease of 88.9% versus 2007, when the company's sales were $97,900.00 .
  Stock Performance Chart for Genethera, Inc.
  Stock Data: Recent Stock Performance:
  Current Price (6/18/2021): .04
(Figures in U.S. Dollars)
1 Week 0.0%   13 Weeks -0.5%  
4 Weeks 8.1%   52 Weeks 53.8%  
Genethera, Inc. Key Data:
  Ticker: GTHR Country: United States
  Exchanges: OTC Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Biological Products Exc. Diagnostic
  2008 Sales 10,822
(Year Ending Jan 2009).
Employees: 2
  Currency: U.S. Dollars Market Cap: 1,022,850
  Fiscal Yr Ends: December Shares Outstanding: 25,571,255
  Share Type: Common Closely Held Shares: 3,708,867
Sponsored Links
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.